KTTAW · Pasithea Therapeutics Corp.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-17 | Coastlands Capital LP |
10% Owner |
Buy↑
Filing footnotes — Common Stock (Indirect)
Coastlands Capital LP ("Coastlands") and Coastlands Capital GP LLC (the "General Partner") are the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, a Delaware limited partnership (the "Partnership"). Coastlands Capital LLC ("Coastlands GP") is the general partner of Coastlands. Matthew Perry is the control person of Coastlands, the Partnership, Coastlands GP and the General Partner. The reporting persons are filing this Form 4 jointly, but not as members of a group, and each disclaims membership in a group. Each reporting person also disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein. |
Common Stock
(I)
|
100,000 |
| 2026-05-01 | Krishnan Kartik |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). |
Stock Option (right to buy)
|
1,129,323 |
| 2026-05-01 | Novak Alfred J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
152,783 |
| 2026-05-01 | Leahy Emer |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
152,783 |
| 2026-05-01 | Dumesnil Simon |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
152,783 |
| 2026-05-01 | STEINMAN LAWRENCE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
152,783 |
| 2026-05-01 | Schneiderman Daniel H |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). |
Stock Option (right to buy)
|
1,129,323 |
| 2026-05-01 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). |
Stock Option (right to buy)
|
1,756,069 |
| 2026-05-01 | Krishnan Kartik |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-11-28 | Leahy Emer |
Director |
Award↑
|
Common Stock
|
33,333 |
| 2025-11-28 | Schneiderman Daniel H |
Chief Financial Officer |
Award↑
|
Common Stock
|
26,667 |
| 2025-11-28 | STEINMAN LAWRENCE |
Director |
Buy↑
|
Common Stock
|
133,333 |
| 2025-11-28 | Marques Tiago |
Director, Chief Executive Officer |
Buy↑
|
Common Stock
|
33,333 |
| 2025-11-28 | Dumesnil Simon |
Director |
Buy↑
|
Common Stock
|
33,333 |
| 2025-10-24 | Novak Alfred J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
42,913 |
| 2025-10-24 | Dumesnil Simon |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
42,913 |
| 2025-10-24 | STEINMAN LAWRENCE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
242,913 |
| 2025-10-24 | Schneiderman Daniel H |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). |
Stock Option (right to buy)
|
317,266 |
| 2025-10-24 | Leahy Emer |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). |
Stock Option (right to buy)
|
42,913 |
| 2025-10-24 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting dates; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan). Additionally, all vested and exercisable shares underlying the Option held by the grantee may be exercised by the grantee for a period of up until three (3) years following termination of Continuous Service (as defined in the Plan), other than a termination for Cause (as defined in the Plan). |
Stock Option (right to buy)
|
493,341 |
| 2025-05-12 | Marques Tiago |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
The Reporting Person previously held 960 shares of Common Stock of the Issuer in a foreign brokerage account that was recently wound down. As a result, the foreign broker automatically liquidated the Reportion Person's account on May 12, 2025 by selling the 960 shares of Common Stock of the Issuer on a non-discretionary basis. |
Common Stock
|
960 |
| 2024-06-13 | Novak Alfred J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.55 to $5.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
Common Stock
|
2,750 |
| 2024-06-12 | Novak Alfred J |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.60 to $5.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
Common Stock
|
750 |
| 2024-03-01 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains a director or otherwise in continuous service to the Issuer through such vesting date. |
Stock Option (right to buy)
|
15,000 |
| 2024-03-01 | Schneiderman Daniel H |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024. |
Stock Option (right to buy)
|
5,927 |
| 2024-03-01 | Currie Graeme Martin |
Chief Development Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The Option fully vested upon issuance and became exercisable on March 1, 2024. |
Stock Option (right to buy)
|
5,938 |
| 2024-03-01 | Novak Alfred J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. |
Stock Option (right to buy)
|
5,000 |
| 2024-03-01 | STEINMAN LAWRENCE |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. |
Stock Option (right to buy)
|
7,500 |
| 2024-03-01 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024. |
Stock Option (right to buy)
|
11,669 |
| 2024-03-01 | Leahy Emer |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award (the "Option") was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. |
Stock Option (right to buy)
|
7,500 |
| 2024-03-01 | Schneiderman Daniel H |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of Common Stock underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting date. |
Stock Option (right to buy)
|
10,000 |
| 2024-03-01 | Dumesnil Simon |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share. The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date. |
Stock Option (right to buy)
|
7,500 |
| 2023-06-02 | STEINMAN LAWRENCE |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.38 to $0.45 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. |
Common Stock
|
30,000 |
| 2022-11-28 | STEINMAN LAWRENCE |
Director |
Award↑
|
Common Stock
|
5,000 |
| 2022-11-25 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
2,000 |
| 2022-11-23 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,000 |
| 2022-11-23 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
1,000 |
| 2022-11-23 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
1,206 |
| 2022-11-22 | STEINMAN LAWRENCE |
Director |
Award↑
|
Common Stock
|
5,000 |
| 2022-11-17 | Dumesnil Simon |
Director |
Award↑
|
Common Stock
|
40,000 |
| 2022-11-15 | Dumesnil Simon |
Director |
Award↑
|
Common Stock
|
10,000 |
| 2022-10-26 | STEINMAN LAWRENCE |
Director |
Award↑
|
Common Stock
|
5,000 |
| 2022-10-21 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
4,400 |
| 2022-10-21 | Novak Alfred J |
Director |
Award↑
Filing footnotes — Stock Option (to acquire Common Stock) (Direct)
The Reporting Person was granted 100,000 stock options. The stock options have a ten-year term and vest over two years, subject to Mr. Novak's continued service as a director, one-half vesting on the first anniversary of the grant date, and the remaining 50% vesting on the second anniversary of the grant date. |
Stock Option (to acquire Common Stock)
|
100,000 |
| 2022-10-21 | Marques Tiago |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
600 |
| 2022-10-17 | Delaney David |
Insider |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President. 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation. |
Common Stock
(I)
|
1,000 |
| 2022-10-11 | Schneiderman Daniel H |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (to acquire Common Stock) (Direct)
The Reporting Person was granted 300,000 stock options. The stock options have a ten-year term and vest over three years, subject to Mr. Schneiderman remaining employed and in good standing, one-third vesting 12 months after the grant date, and the remainder vesting in equal tranches monthly for two years thereinafter. |
Stock Option (to acquire Common Stock)
|
300,000 |
| 2022-09-29 | Shahinian Eric |
Insider |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC. |
Common Stock
(I)
|
6,710 |
| 2022-09-28 | Shahinian Eric |
Insider |
Buy↑
Filing footnotes — Common Stock (Indirect)
The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC. |
Common Stock
(I)
|
57,647 |
| 2022-09-14 | Novak Alfred J |
Director |
Other↑
|
No Securities Owned
|
0 |